ChromaDex (CDXC)
(Delayed Data from NSDQ)
$2.67 USD
+0.23 (9.43%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $2.67 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Brokerage Reports
ChromaDex Corporation [CDXC]
Reports for Purchase
Showing records 41 - 60 ( 115 total )
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage With Buy Rating and 12-Month Price Target of $7
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
New Continuation Patent Issued; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Designs for Health Partnership; Pilot Trial Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Marketing Strategy Evolving; 3Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Sinopharm Xingsha Partnership; California Trial Concluded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Summary Judgment Ruling Non-Impactful, in Our View
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Top and Bottom-Line Beat; Tailwinds Intensifying; Raising PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
TRU NIAGEN Brand Launched Through Walmart; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Top- and Bottom-Line Miss; 1Q21 Financial Results; Reducing PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Nestle Key Acquisition Underscores Strategic Value of Supplements; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Revenue Trajectory Promising; Multiple Recent Advances; Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Evidence Mounts of Nicotinamide Riboside Impact on COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Top- and Bottom-Line Beat; 2Q20 Financials; Raising PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Potential NIAGEN Applicability in Autism; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
New Coronavirus Cell Model Data Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
1Q20 Financials; Top- and Bottom-Line Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
COVID-19 Research Promise; Beauty Product Launched; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R